In the ADAURA phase III trial, Tagrisso from AstraZeneca showed a significant improvement in overall survival for patients with early-stage EGFR-mutated lung cancer.

Statistically significant and clinically meaningful improvements in overall survival (OS), a crucial secondary endpoint, were seen with AstraZeneca’s Tagrisso (osimertinib) compared to placebo in the adjuvant treatment of patients with early-stage (IB, II, and IIIA) epidermal growth factor receptor-mutated (EGFRm)…

For biological applications like delivering medications to diseased cells, IISc creates chemically altered nanosheets.

Researchers from the Department of Organic Chemistry (DOC) and the Materials Research Center (MRC) at the Indian Institute of Science (IISc) have demonstrated that surface modifications of two-dimensional molybdenum disulphide (2D-MoS) nanosheets can greatly increase their effectiveness for uses like…

Back to top

Registration Form


This will close in 0 seconds

WhatsApp Join Telegram